HMP recommends approval of extension to Cervarix® human papillomavirus vaccine therapeutic indication

Source: European Medicines Agency Area: News The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of an extension to the therapeutic indication for the Cervarix® human papillomavirus vaccine.   The full proposed indication would be as follows (with the changes in bold):   "Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant genital (cervical, vulvar and vaginal) lesions and cervical cancer causally related to certain oncogenic human papillomavirus (HPV) types."   Detailed recommendations for the use of this product will be described in the updated Summary of Product Characteristics, which will be available after the variation to the marketing authorisation has been granted by the European Commission.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news